R&D at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's R&D?
- Axsome Therapeutics (AXSM) reported R&D of $52.68M in Q1 2026.
- How has Axsome Therapeutics's R&D changed year-over-year?
- Axsome Therapeutics's R&D increased by 17.6% year-over-year, from $44.79M to $52.68M.
- What is the long-term trend for Axsome Therapeutics's R&D?
- Over 4 years (2021 to 2025), Axsome Therapeutics's R&D has grown at a 33.3% compound annual growth rate (CAGR), from $58.06M to $183.28M.
- What does R&D mean?
- Spending dedicated to the discovery and clinical development of new medical treatments.
- How do you interpret R&D?
- Higher spending indicates a robust pipeline investment, though it may temporarily reduce current profitability.
- How does R&D compare across companies?
- High for clinical-stage biotechs; investors compare this against the size and stage of the clinical pipeline.